By Gilang Cahya 
Researchers have uncovered a critical link between age-related genetic changes in blood cells and the progression of cancerous tumors, a discovery that could reshape our understanding of cancer development and open new avenues for treatment and prevention. The groundbreaking study, published in the prestigious New England Journal of Medicine, reveals that clonal hematopoiesis of indeterminate potential (CHIP), a common phenomenon in aging individuals where blood stem cells accumulate mutations, can actively infiltrate solid tumors and significantly worsen patient prognoses. This research, a collaborative effort involving institutions such as the Francis Crick Institute, University College London (UCL), Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK), offers vital insights into the complex interplay between aging, genetic instability, and the pathogenesis of cancer.
The Hidden Impact of Ageing on Cancer: Unveiling CHIP
As global populations age, understanding the biological mechanisms that bridge age-related genetic alterations and diseases of aging, including cancer and cardiovascular disease, becomes paramount. These advancements are crucial for developing effective preventative therapies for an increasingly elderly demographic. Clonal hematopoiesis of indeterminate potential (CHIP) is a condition characterized by the gradual accumulation of mutations in blood stem cells. This process is influenced by both the natural aging process and external environmental factors, such as exposure to toxins or radiation. While CHIP has previously been associated with an increased risk of age-related disorders like cardiovascular disease, its specific role in the evolution and progression of solid cancers has remained largely unexplored until now.
The current study, a comprehensive investigation into the nexus of CHIP and cancer, meticulously analyzed data from over 400 lung cancer patients involved in the Cancer Research UK-funded TRACERx and PEACE studies. This was complemented by an extensive dataset of 49,000 patients with diverse cancer types from Memorial Sloan Kettering Cancer Center. This dual approach provided a robust foundation for drawing significant conclusions about the widespread implications of CHIP in the oncological landscape.
CHIP in Tumors: A Harbinger of Worse Prognosis
The initial phase of the research involved analyzing blood samples from patients to identify the presence of CHIP mutations. When this genetic information was correlated with clinical data, a stark pattern emerged: patients with CHIP mutations in their blood had a significantly shorter survival period, irrespective of their age at diagnosis or the stage of their cancer. This observation underscored the intrinsic link between these age-related genetic changes and a more aggressive disease course.
The researchers then delved deeper, investigating whether these CHIP mutations were also present within the lung tumors themselves, suggesting an infiltration of mutated blood cells. Their findings confirmed this suspicion in a substantial 42% of patients with CHIP. They coined this phenomenon "tumour infiltrating clonal haematopoiesis" (TI-CH). Crucially, it was not the mere presence of CHIP in the blood, but rather its infiltration into the tumor (TI-CH), that proved to be the significant predictor of an increased risk of cancer relapse and mortality.
This critical finding was further corroborated by data from the PEACE study, a postmortem investigation specifically examining metastatic sites – the areas where cancer spreads and the primary cause of cancer-related deaths. The research team observed that metastatic tumors at these disseminated sites frequently harbored TI-CH mutations. This strongly suggests that mutated blood cells are not only present but actively contributing to the spread and lethality of cancer.
Understanding the Mechanism: The Role of TET2 and Myeloid Cells
To unravel the specific mechanisms by which TI-CH contributes to poor patient outcomes, the scientists meticulously examined the cellular composition of lung tumors. They discovered that patients with TI-CH exhibited an expansion of myeloid cells within their tumors. Myeloid cells are a crucial component of the tumor microenvironment. Unlike some immune cells that are programmed to recognize and combat cancer, myeloid cells have been shown to modulate inflammatory responses and can actively promote tumor progression and metastasis.
Further investigation revealed a specific genetic culprit: mutations in the TET2 gene. TET2 plays a vital role in regulating blood cell production. The study found that when mutations affected TET2, the resulting mutant blood cells were more likely to infiltrate tumors. Analysis of hundreds of individual cells from the tumors of two patients with TI-CH confirmed that TET2 mutations were predominantly found in myeloid cells, with minimal presence in other immune cell types.
In a critical experimental validation, the research team collaborated with experts in blood cancer and CHIP at the Crick institute, led by Dominique Bonnet. They created organoids – miniature, lab-grown tumors – incorporating TET2-mutant myeloid cells. These experiments demonstrated that TET2-mutant myeloid cells could actively remodel the tumor microenvironment and accelerate the growth of these organoid tumors. This provides compelling evidence of a direct causal link between specific CHIP mutations in myeloid cells and enhanced tumor aggressiveness.
Broadening the Scope: Implications Across Cancer Types
The implications of these findings extend far beyond lung cancer. In collaboration with researchers at Memorial Sloan Kettering Cancer Center in the US, the team analyzed an even larger dataset comprising over 49,000 patients with various cancer types. Their findings consistently showed that the presence of TI-CH was an independent predictor of shorter survival across different malignancies.
However, the prevalence of CHIP and TI-CH varied depending on the cancer type. Notably, these mutations were found to be more common in cancers that are notoriously difficult to treat, such as lung cancer, head and neck cancer, and pancreatic cancer. This observation suggests that CHIP may play a particularly significant role in the progression of more aggressive and treatment-resistant cancers, highlighting a critical unmet need in these areas.
Future Directions and Potential Interventions
The researchers emphasize that the next crucial steps involve confirming that CHIP directly contributes to cancer outcomes and meticulously detailing the precise mechanisms by which it functionally implicates itself in the development of aggressive cancers. This ongoing work aims to translate these fundamental discoveries into tangible clinical benefits.
Dr. Oriol Pich, a lead researcher on the project and Postdoctoral Project Research Scientist at the Crick, stated, "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer." This sentiment is echoed by Professor Charlie Swanton, Deputy Clinical Director at the Crick and Chief Clinician at Cancer Research UK, who commented, "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’, age-related CHIP and cancer, providing insight into how ageing might impact cancer risk."
Professor Swanton further elaborated on the potential for intervention: "As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers."
Broader Impact and Implications for Public Health
This seminal research has profound implications for the future of cancer care and public health strategies. The identification of TI-CH as a distinct prognostic marker could lead to improved risk stratification for cancer patients. Patients found to have TI-CH might benefit from more intensive monitoring or tailored treatment regimens.
Furthermore, understanding the role of age-related mutations in cancer development could pave the way for novel preventative strategies. If specific genetic changes in blood cells are found to predispose individuals to certain cancers, it might be possible to develop interventions that target these early cellular alterations or mitigate their impact. This could include pharmacological agents that inhibit the expansion of mutant blood cells or strategies that bolster the immune system’s ability to detect and eliminate cells with these mutations.
The study’s reliance on large, well-characterized patient cohorts, including the TRACERx and PEACE studies funded by Cancer Research UK, and data from Memorial Sloan Kettering Cancer Center, lends significant weight and generalizability to its findings. The collaborative nature of the research, involving multiple leading international institutions, underscores the global effort to unravel the complex biology of aging and cancer.
The work was supported by a consortium of esteemed organizations, including Cancer Research UK, the National Institute of Health and Care Research UCLH Biomedical Research Centre, and other undisclosed funders, highlighting the critical importance of sustained investment in fundamental scientific research. The identification of TI-CH as a significant factor in cancer progression marks a pivotal moment in cancer research, opening exciting new frontiers for therapeutic development and offering a glimmer of hope for improving outcomes for millions of patients worldwide. The ongoing investigations into the precise molecular mechanisms and clinical applications of these findings are eagerly anticipated by the scientific and medical communities.
